Payment overview · 2025
General Payments
$1,046.48
54 reported records · 23 companies
Healthcare provider profile · identity verified
John-Stewart Michael Smith, MD
Allopathic & Osteopathic Physicians|Family Medicine · JAY, FL · NPI 1497710313
Verified facts
What the public records show
CMS Open Payments records show John-Stewart Michael Smith, MD received $1,046.48 in general payments during 2025 across 54 reported records.
AstraZeneca Pharmaceuticals LP accounted for 18.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 249 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $191.16 | 18.3% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $137.06 | 13.1% | 9 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $135.76 | 13.0% | 11 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $88.44 | 8.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $71.46 | 6.8% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $60.15 | 5.8% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $46.99 | 4.5% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $29.30 | 2.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.06 | 2.7% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $24.17 | 2.3% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $23.16 | 2.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.95 | 2.2% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $21.37 | 2.0% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.28 | 2.0% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $18.46 | 1.8% | 1 | 2025 |
| Biosense Webster, Inc. | Unresolved — no canonical attribution shown | $18.02 | 1.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.08 | 1.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.47 | 1.6% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.99 | 1.5% | 1 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $15.86 | 1.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.66 | 1.5% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $14.71 | 1.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.92 | 1.2% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,046.48 | 54 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $191.16 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $165.06 | 12 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $143.27 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $143.27 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $103.55 | 7 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $88.44 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $72.17 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $71.46 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $71.46 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $46.99 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $43.50 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $30.85 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $28.06 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $24.17 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $23.16 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $22.95 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $21.37 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| CARTO 3 Normalized: carto 3 |
Device | Biosense Webster, Inc. | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.47 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $14.71 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.92 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 72 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 249 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 60 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
52 | 13 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
72 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
60 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
72 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
249 | 40 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
131 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 557 | 127 |
| Omeprazole | Omeprazole | 516 | 134 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 502 | 119 |
| Levothyroxine Sodium | Levothyroxine Sodium | 485 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 391 | 90 |
| Potassium Chloride | Potassium Chloride | 388 | 84 |
| Gabapentin | Gabapentin | 383 | 99 |
| Atorvastatin Calcium | Atorvastatin Calcium | 379 | 92 |
| Furosemide | Furosemide | 363 | 82 |
| Metoprolol Succinate | Metoprolol Succinate | 355 | 84 |
| Meloxicam | Meloxicam | 285 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 261 | 58 |
| Lisinopril | Lisinopril | 261 | 65 |
| Metformin Hcl | Metformin Hcl | 252 | 53 |
| Ozempic | Semaglutide | 249 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 236 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 229 | 51 |
| Simvastatin | Simvastatin | 226 | 47 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 220 | 47 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 216 | 60 |
| Trazodone Hcl | Trazodone Hcl | 200 | 59 |
| Doxepin Hcl | Doxepin Hcl | 187 | 44 |
| Diclofenac Sodium | Diclofenac Sodium | 180 | 46 |
| Azithromycin | Azithromycin | 164 | 111 |
| Pioglitazone Hcl | Pioglitazone Hcl | 164 | 43 |
| Tizanidine Hcl | Tizanidine Hcl | 156 | 62 |
| Ondansetron Hcl | Ondansetron Hcl | 152 | 64 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 150 | 47 |
| Amoxicillin | Amoxicillin | 150 | 104 |
| Carvedilol | Carvedilol | 144 | 32 |
| Allopurinol | Allopurinol | 143 | 30 |
| Sertraline Hcl | Sertraline Hcl | 141 | 36 |
| Ibuprofen | Ibuprofen | 139 | 35 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 137 | 102 |
| Escitalopram Oxalate | Escitalopram Oxalate | 134 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 134 | 36 |
| Metformin Hcl Er | Metformin Hcl | 132 | 31 |
| Eliquis | Apixaban | 131 | 21 |
| Cefdinir | Cefdinir | 128 | 84 |
| Ropinirole Hcl | Ropinirole Hcl | 124 | 23 |
| Donepezil Hcl | Donepezil Hcl | 120 | 20 |
| Prednisone | Prednisone | 117 | 85 |
| Metoprolol Tartrate | Metoprolol Tartrate | 113 | 29 |
| Fenofibrate | Fenofibrate | 110 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 108 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 106 | 23 |
| Tramadol Hcl | Tramadol Hcl | 97 | 43 |
| Pregabalin | Pregabalin | 96 | 19 |
| Celecoxib | Celecoxib | 83 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 82 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 78 | 63 |
| Montelukast Sodium | Montelukast Sodium | 78 | 20 |
| Alprazolam | Alprazolam | 76 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 76 | 16 |
| Clonidine Hcl | Clonidine Hcl | 76 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 75 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 75 | 25 |
| Lorazepam | Lorazepam | 74 | 11 |
| Jardiance | Empagliflozin | 72 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 67 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 67 | 18 |
| Finasteride | Finasteride | 65 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 64 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 63 | 14 |
| Bupropion Xl | Bupropion Hcl | 63 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 60 | 19 |
| Fluconazole | Fluconazole | 60 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 60 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 60 | 34 |
| Memantine Hcl | Memantine Hcl | 59 | suppressed |
| Estradiol | Estradiol | 54 | suppressed |
| Ezetimibe | Ezetimibe | 54 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 54 | suppressed |
| Spironolactone | Spironolactone | 54 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 53 | 15 |
| Naproxen | Naproxen | 53 | 12 |
| Synthroid | Levothyroxine Sodium | 52 | 13 |
| Alendronate Sodium | Alendronate Sodium | 48 | 16 |
| Methocarbamol | Methocarbamol | 48 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 47 | 19 |
| Famotidine | Famotidine | 46 | 12 |
| Mupirocin | Mupirocin | 45 | 29 |
| Xarelto | Rivaroxaban | 44 | suppressed |
| Atenolol | Atenolol | 42 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 42 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 41 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | suppressed |
| Baclofen | Baclofen | 39 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | 12 |
| Topiramate | Topiramate | 38 | suppressed |
| Clonazepam | Clonazepam | 37 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 37 | suppressed |
| Trulicity | Dulaglutide | 37 | suppressed |
| Novolog Flexpen | Insulin Aspart | 36 | suppressed |
| Glipizide | Glipizide | 35 | suppressed |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 30 |
| Dutasteride | Dutasteride | 34 | 11 |
| Promethazine Hcl | Promethazine Hcl | 34 | 14 |
| Terbinafine Hcl | Terbinafine Hcl | 34 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 31 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Bumetanide | Bumetanide | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Glimepiride | Glimepiride | 29 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 28 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 13 |
| Colchicine | Colchicine | 27 | 12 |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Loperamide | Loperamide Hcl | 26 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 25 | 13 |
| Sucralfate | Sucralfate | 25 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Ibu | Ibuprofen | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Nystatin | Nystatin | 21 | 12 |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 21 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Ketoconazole | Ketoconazole | 19 | 11 |
| Klor-Con 10 | Potassium Chloride | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 18 | 17 |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Humalog | Insulin Lispro | 15 | suppressed |
| Insulin Lispro | Insulin Lispro | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | 11 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | 13 |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Ramipril | Ramipril | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Ofloxacin | Ofloxacin | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Tobramycin | Tobramycin | 11 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,046.48 · 54 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, AIRSUPRA, APRETUDE, AUSTEDO XR, BREZTRI, CAPLYTA, CARTO 3, Dexcom G6 Transmitter, FARXIGA, GEMTESA, GVOKE HYPOPEN, IBSRELA, JARDIANCE, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VOQUEZNA, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error